What is Corbus Pharmaceuticals Holdings Quick Ratio?
Corbus Pharmaceuticals HoldingsCRBP -3.20%31 Quick Ratio is 7.92 as of Mar. 2026, which is 65% above its 10-year median of 4.79. GuruFocus rates CRBP with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,412 Biotechnology companies, Corbus Pharmaceuticals Holdings ranks better than 72.45% on this metric.
Corbus Pharmaceuticals Holdings has a quick ratio of 7.92. It generally indicates good short-term financial strength.
The historical rank and industry rank for Corbus Pharmaceuticals Holdings's Quick Ratio or its related term are showing as below:
CRBP'
s Quick Ratio Range Over the Past 10 Years
Min: 0.74 Med: 4.79 Max: 13.84
Current: 7.92
During the past 13 years, Corbus Pharmaceuticals Holdings's highest Quick Ratio was 13.84. The lowest was 0.74. And the median was 4.79.
CRBP's Quick Ratio is ranked better than 72.45% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs CRBP: 7.92
Corbus Pharmaceuticals Holdings (NAS:CRBP) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Corbus Pharmaceuticals Holdings Quick Ratio Related Terms
Corbus Pharmaceuticals Holdings Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corbus Pharmaceuticals Holdings Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Corbus Pharmaceuticals Holdings's Quick Ratio falls into.
Corbus Pharmaceuticals Holdings Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corbus Pharmaceuticals Holdings (CRBP) has a Quick Ratio of 7.92 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Corbus Pharmaceuticals Holdings and its competitors. This is 65% above median its historical median of 4.79. Over the past decade, Corbus Pharmaceuticals Holdings' Quick Ratio has ranged from 0.74 to 13.84. According to the industry distribution chart, Corbus Pharmaceuticals Holdings ranks #389 out of 1412 companies in the Biotechnology industry, placing it in the top 27.5%.
Is Corbus Pharmaceuticals Holdings' Quick Ratio too high?
Corbus Pharmaceuticals Holdings' current Quick Ratio of 7.92 is 65% above median its 10-year median of 4.79. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 13.84. The Biotechnology industry median Quick Ratio is 3.60. Corbus Pharmaceuticals Holdings' value of 7.92 is 120% above this industry median. Based on the distribution chart, Corbus Pharmaceuticals Holdings ranks #389 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' Quick Ratio compare to PRQR and NRXP?
According to the Biotechnology industry distribution chart, Corbus Pharmaceuticals Holdings ranks #389 out of 1412 companies for Quick Ratio. This puts Corbus Pharmaceuticals Holdings in the upper half of its industry. The industry median Quick Ratio is 3.60. Corbus Pharmaceuticals Holdings' value of 7.92 is 120% above this benchmark. Historically, Corbus Pharmaceuticals Holdings' own Quick Ratio has ranged from 0.74 to 13.84 over the past decade. While the company's 10-year median is 4.79 vs. the industry median of 3.60, Corbus Pharmaceuticals Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corbus Pharmaceuticals Holdings's current Quick Ratio of 7.92 is 120% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Corbus Pharmaceuticals Holdings and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corbus Pharmaceuticals Holdings's current Quick Ratio is 7.92, which is 65% above median its own 10-year median of 4.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Corbus Pharmaceuticals Holdings (CRBP) has a current Quick Ratio of 7.92. The current Quick Ratio is 7.92, which is 65% above median its 10-year median of 4.79 and 120% above the Biotechnology industry median of 3.60. Corbus Pharmaceuticals Holdings' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (CRBP), the current Quick Ratio is 7.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corbus Pharmaceuticals Holdings Business Description
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
31GF Score
Get the complete analysis for CRBP
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRBP has been successfully added to your 
